Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Beijing Biostar Pharmaceuticals Co. Ltd. primarily focuses on developing innovative therapies for tumors. The company is dedicated to creating novel anti-cancer drugs, each secured by independent intellectual property rights. A prominent product in its portfolio is the Utidelone injection, a next-generation microtubule inhibitor produced through a unique microbial fermentation process. This enterprise was co-founded by Li Tang and Rong Guo Qiu on July 11, 2002, and operates from its headquarters in Beijing, China.
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. Specifically, the stock is fairly valued on P/E, undervalued on EV/EBITD.